Subjects eligible for this clinical trial include patients who have been on Coumadin  (warfarin) to treat a blood clot in the legs or lungs that developed in the past 6-18 months. This study is evaluating an investigational medicine to determine its efficacy in preventing recurrent blood clots. Unlike Coumadin (warfarin), this drug is not affected by food and does not require repeated blood testing to measure its safety or efficacy. The study will last 6-12 months. Patients who qualify will receive study medication, lab tests, study-related care and physical examinations at no cost.

A novel, oral anticoagulant is being evaluated in persons with a recent Acute Coronary Syndrome / Heart Attack. This study is expected to last for an average of 28 months. The study medication will administered in addition to  the standard of care for this condition in order to determine if it prevents cardiovasclar events better than the standard of care. Patients who qualify will receive study medication, lab tests, study-related care and physical examinations at no cost.

This study is evaluating the whether a novel cholesterol medication decreases the risk of cardiovascular events in persons with a recent acute coronary syndrome. Persons who have recently been hospitalized with an Acute Coronary Syndrome / Heart Attack may be eligible to participate in this 2-year study. Patients who qualify will receive study medication, lab tests, study-related care and physical examinations at no cost.

The study will evaluate the ability of an investigational drug to prevent gouty attacks in persons at risk of experiencing such attacks. The study drug is administered subcutaneously once-per-week. Patients who qualify will receive study medication, lab tests, study-related care and physical examinations at no cost.

A novel blood thinner is being compared with Coumadin (warfarin) in this two year study which will compare the risk of stroke/TIA (mini-stroke)/systemic embolism in persons with atrial fibrillation and risk factors for stroke.  Unlike Coumadin (warfarin), this drug is not affected by food and does not require repeated blood testing to measure its safety or efficacy. Patients who qualify will receive study medication, lab tests, study-related care and physical examinations at no cost.

Patients with ulcerative colitis are eligible to participate in this two year clinical trial evaluating the efficacy and safety of an investigational intravenous drug for the treatment of ulcerative colitis. Study drug administration will occur each month by IV infusion and participants will be observed after drug administration. Subjects who respond well may proceed to an extension study with open label study drug during a maintenance phase. Patients who qualify will receive study medication, lab tests, study-related care and physical examinations at no cost.

Patients with Crohn’s disease are eligible to participate in this two year clinical trial evaluating the efficacy and safety of an investigational intravenous drug for the treatment of Crohn's disease. Study drug administration will occur by IV infusion each month and participants will be observed after drug administration. Subjects who respond well may proceed to an extension study with open label study drug during a maintenance phase. Patients who qualify will receive study medication, lab tests, study-related care and physical examinations at no cost.

Persons with high blood pressure who require medicine will be treated with FDA approved medicines for high blood pressure. Sexual function will be evaluated during this 28-week study. Women over the age of 50 who are postmenopausal and have high blood pressure might be eligible for this study. Patients who qualify will receive study medication, lab tests, study-related care and physical examinations at no cost.

Insulin plays a pivotal role in the treatment of type 2 diabetes. Recently, physicians are utilizing insulin, in addition to oral agents, earlier and more often in persons with type 2 diabetes to increase the likelihood of achieving blood glucose goals and improving outcomes. This study will evaluate the efficacy and safety of a novel insulin preparation versus standard insulin therapy in persons with type 2 diabetes. Each insulin is administered once daily in combination with metformin or metformin and other oral agents. Subjects eligible for this trial have type diabetes and an HbA1c  between 7.0 – 10.0 % despite treatment with a stable oral antidiabetic regimen.

This is a hospital based study  that tests the ability of a novel, investigational medication given in addition to standard therapy, to improve symptoms of congestive heart failure (CHF).  Eligible subjects are seen in the hospital ER for CHF, and must be between the ages of 18 and 65, have mild to moderate renal impairment, and are presently receiving standard therapies for their heart  failure.

This is a study comparing generic Celebrex against various commonly used non steroidal anti- inflammatory drugs (NSAIDs) for the treatment of osteoarthritis or rheumatoid arthritis. A clinical diagnosis of Osteoarthritis or Rheumatoid arthritis must be documented for 6 months prior to enrollment in study. This is a long term study that will last approximately 3 years. Eligible patients will receive study related exams,medications and lab tests at no cost. Compensation for time and travel may be offered.